Vioxx
Celebrex
Bextra
COX-2 Inhibitors
Crestor
Neurontin
Zyprexa
Ephedra
Strattera
Remicade
Accutane
Serzone
Serevent
Tamoxifen
Baycol
Fen Phen
Rezulin
Meridia
PPA
Propulsid
Avara
Permax
Anti-Depressants
OxyContin
Tysabri
Pemoline
 
Guidant Defibrillators
Guidant Ancure Device
Sulzer Hip Replacement
Contraceptive Devices
Breast Implants
 
Welding Rods
Asbestos
Mesothelioma
Lead Poisoning
Silica
 
Cerebral Palsy
Erb's Palsy
Birth Injury
Surgical Mistake
Cancer Misdiagnosis
Nursing Home Negligence
Hospital Negligence
 
Car Accidents
Plane Accidents
Boat Accidents
Bus Accidents
Motorcycle Acc
Brain Injury
Spinal Cord Injury
Dodge Truck and SUV Recall
 
Insurance Bad Faith
Slip and Fall
Dog Bite Injury
Inadequate Security
Recall Forum
Consumer Pro
Sexual Abuse
Product Liability
General Inquiries

Resources

Network

Peers

COX-2 Inhibitors Information

    COX-2 Inhibitors include the drugs Vioxx® (rofecoxib), Bextra® (valdecoxib) and Celebrex® (celecoxib).  COX-2 inhibitors are nonsteroidal anti-inflammatory drugs, or NSAIDs, and are prescribed to treat arthritis and muscle pain.  Numerous studies have found increased risk of heart attack, stroke, and blood clots in patients using COX-2 inhibitors.  This class of drugs was intended to treat pain but with decreased gastrointestinal side effects associated with the older NSAIDs such as ibuprofen and naproxen. COX-2 inhibitors work by blocking the COX-2 enzyme, whereas the older NSAIDs block both COX-1 and COX-2 enzymes.

    Vioxx® was withdrawn by Merck and Co. on September 30, 2004 after a study was released demonstrating an increased risk of heart attack, stroke and blood clots.

 


    Bextra® was withdrawn by Pfizer on April 7, 2005 due to the drug’ s side effects including heart attack, stroke, blood clots, and skin disorders such as Stevens Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
Celebrex® is the only COX-2 inhibitor that remains on the market.  

    Many doctors and patients have criticized Merck, Pfizer and the FDA for allowing Vioxx®, Bextra® and Celebrex® to remain on the market for years following their approval despite numerous early findings of serious and potentially fatal cardiovascular risks and skin disorders.


Avarage rating: 5.00
Rating: 5
From: taher al kasaby
gastric irritation was clear in 50 % of my patient using celebrex ... but less than other cox 1 -2 inhibitor



Please share your opinion with us.
Your name:
Your email:
How dangerious do you think this is?:
Write a review for this product:

Copyright 2006 LawsuitResources.com
Flights to New York - Calorad - Tesco Loans - Ponsonby Accommodation - Background Checks